Industry
Biotechnology
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 10:10 pm
Portfolio Pulse from Benzinga Insights
June 13, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:38 pm
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 3:04 pm
Portfolio Pulse from Avi Kapoor
April 26, 2024 | 5:56 pm
Portfolio Pulse from Henry Khederian
April 26, 2024 | 3:31 pm
Portfolio Pulse from Benzinga Insights
April 26, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
April 26, 2024 | 12:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.